[go: up one dir, main page]

WO2023125729A1 - Anticorps humanisé anti-cd3 et son utilisation dans la préparation d'un anticorps bispécifique - Google Patents

Anticorps humanisé anti-cd3 et son utilisation dans la préparation d'un anticorps bispécifique Download PDF

Info

Publication number
WO2023125729A1
WO2023125729A1 PCT/CN2022/143043 CN2022143043W WO2023125729A1 WO 2023125729 A1 WO2023125729 A1 WO 2023125729A1 CN 2022143043 W CN2022143043 W CN 2022143043W WO 2023125729 A1 WO2023125729 A1 WO 2023125729A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
acid sequence
seq
antibody
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/143043
Other languages
English (en)
Chinese (zh)
Inventor
宁金鹰
彭浩
郝锋
贺锋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyinno Biotechnology Co Ltd
Original Assignee
Kyinno Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyinno Biotechnology Co Ltd filed Critical Kyinno Biotechnology Co Ltd
Publication of WO2023125729A1 publication Critical patent/WO2023125729A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues

Definitions

  • the invention belongs to the field of biomedicine, in particular, the invention relates to an anti-human CD3 humanized antibody or its functional fragment, and the application of the antibody or its functional fragment.
  • CD3 molecule is mainly distributed on the surface of mature T lymphocytes, and is an important differentiation antigen on the membrane of T cells. Studies have shown that CD3 molecules are composed of at least five polypeptide chains: gamma ( ⁇ ), delta ( ⁇ ), epsilon ( ⁇ ), zeta ( ⁇ ), and Eta ( ⁇ ); among them, CD3-epsilon is related to CD3-gamma, CD3-delta and CD3-zeta and heterodimers of the T cell receptors alpha/beta and gamma/delta together constitute the T cell receptor (TCR)-CD3 complex.
  • TCR T cell receptor
  • the TCR-CD3 complex plays an important role in coupling antigen recognition to intracellular signal transduction pathways: part of the TCR-CD3 complex exists on the surface of T lymphocytes, and when antigen-presenting cells (APCs) activate TCR, TCR-mediated
  • APCs antigen-presenting cells
  • TCR-mediated The signal induced by the CD3 molecule is transmitted on the cell membrane through CD3-delta, CD3-epsilon, CD3-gamma and CD3-zeta, and all CD3 molecules contain an immunoreceptor tyrosine activation domain (ITAM) in their cytoplasmic domain, in Following TCR engagement, these domains are phosphorylated by the src family of protein tyrosine kinases LCK and FYN, leading to activation of downstream signaling pathways.
  • ITAM immunoreceptor tyrosine activation domain
  • the purpose of the present invention is to provide a novel antibody with appropriate affinity for CD3, especially CD3 on the surface of human T cells.
  • Another object of the present invention is to provide the application of the anti-CD3 antibody or the functional regions contained therein (such as heavy chain variable region and light chain variable region) in the preparation of antibody medicine.
  • the present invention provides the following technical solutions.
  • the present invention provides an antibody or fragment thereof, which can specifically bind to CD3, especially CD3 on the surface of human T cells.
  • the antibody or fragment thereof provided by the present invention comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region (VH) and light chain variable region (VL) ) comprising the following CDR combinations (HCDR-1, HCDR-2, HCDR-3; LCDR-1, LCDR-2, LCDR-3): HCDR-1 comprising the amino acid sequence (TYAMN) shown in SEQ ID NO: 22, HCDR-2 comprising the amino acid sequence shown in SEQ ID NO:23 (RIRSKYNNYATYYADSVKD), HCDR-3 comprising the amino acid sequence shown in SEQ ID NO:24 (HGNFGNSYVSYFAY); and, comprising the amino acid shown in SEQ ID NO:25 LCDR-1 of sequence (RSSTGAVTTSNYAN), LCDR-2 comprising the amino acid sequence (GTNKRAP) shown in SEQ ID NO:26, LCDR-3 comprising the amino acid sequence (ALWYSNLWV) shown in SEQ ID NO:27
  • the combination of light and heavy chain CDRs provided comes from the heavy chain and light chain amino acid sequences of the anti-CD3 antibody specifically described in the specific embodiments of the present invention.
  • CDRs contained in the chain and light chain For example, the combinations of light and heavy chain CDRs provided above were obtained using the KABAT definition method.
  • the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 7 or an amino acid sequence having at least 75% identity with the amino acid sequence; and/or Alternatively, the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 8 or an amino acid sequence at least 75% identical to said amino acid sequence.
  • At least 75% identity is an identity of any percentage figure between 75% and 100%, such as 75%, 80%, 85%, 90%, or even 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or even 100% identity.
  • both the "heavy chain variable region” and the “light chain variable region” include the above-mentioned CDR combination and the spaced framework region (framework region), and the arrangement of each structural domain is: FR1-CDR1-FR2 - CDR2-FR3-CDR3-FR4.
  • at most 25% difference in amino acid sequence resulting from said "at least 75% identity” may exist in any framework region in the heavy chain variable region or light chain variable region, or in the heavy chain variable region. In any domain or sequence other than the variable region and light chain variable region. The differences may result from amino acid deletions, additions or substitutions at any position.
  • the antibody or fragment thereof of the present invention is an anti-CD3 antibody or fragment thereof; preferably, the antibody is mouse anti, rabbit anti, monoclonal antibody, chimeric antibody, partially or fully humanized antibody etc., or the fragment is a half antibody or an antigen-binding fragment of an antibody or half antibody, such as scFv, BsFv, dsFv, (dsFv)2, Fab, Fab', F(ab')2 or Fv; more preferably Preferably, the antibody is IgG.
  • the present invention provides an isolated and structurally characterized human antibody, such as a human monoclonal antibody, that specifically binds CD3, particularly CD3 on the surface of human T cells.
  • the antibody or fragment thereof provided by the invention also comprises a constant region, such as a human or murine constant region, preferably a human or murine heavy chain constant region (CH) and/or light chain constant region (CL ); preferably, the antibody or fragment thereof comprises a heavy chain and a light chain; more preferably, the antibody or fragment thereof comprises a heavy chain constant region and/or a kappa or lambda type of IgG, IgA, IgM, IgD or IgE Light chain constant region.
  • a constant region such as a human or murine constant region, preferably a human or murine heavy chain constant region (CH) and/or light chain constant region (CL ); preferably, the antibody or fragment thereof comprises a heavy chain and a light chain; more preferably, the antibody or fragment thereof comprises a heavy chain constant region and/or a kappa or lambda type of IgG, IgA, IgM, IgD or IgE Light chain constant region.
  • the antibody is a monoclonal antibody, preferably a murine, chimeric or humanized monoclonal antibody.
  • the heavy chain constant region of the monoclonal antibody is of IgG1 or IgG4 subtype, and the light chain constant region is of ⁇ type.
  • the heavy chain constant region of the monoclonal antibody comprises the amino acid sequence shown in SEQ ID NO: 17 or an amino acid sequence at least 75% identical to the amino acid sequence shown in SEQ ID NO: 17; the monoclonal antibody
  • the light chain constant region of the antibody comprises the amino acid sequence set forth in SEQ ID NO: 18 or an amino acid sequence at least 75% identical to the amino acid sequence set forth in SEQ ID NO: 18.
  • the anti-human CD3 antibody of the present invention is a monoclonal antibody.
  • the anti-human CD3 antibody provided by the present invention is an immunoglobulin, for example, the type of the immunoglobulin is human IgA, IgD, IgE, IgG or IgM. Further preferably, the antibody is of human IgG1 subtype.
  • the present invention also provides a nucleic acid molecule, which comprises a heavy chain CDR, light chain CDR, light chain variable region, heavy chain variable region, heavy chain or Nucleotide sequence of the light chain.
  • the nucleic acid molecule of the present invention can be cloned into a vector, and then transformed or transfected into a host cell.
  • the invention also provides a vector comprising a nucleic acid molecule of the invention.
  • the vector may be a eukaryotic expression vector, a prokaryotic expression vector, an artificial chromosome, a phage vector, and the like.
  • the vectors or nucleic acid molecules of the invention can be used to transform or transfect host cells. Therefore, in a further aspect, the present invention provides a host cell comprising, or transformed or transfected with, the nucleic acid molecule and/or vector of the present invention.
  • the host cell can be any prokaryotic or eukaryotic cell, such as a bacterial or insect, fungal, plant or animal cell.
  • Antibodies or fragments thereof provided by the present invention can be obtained by any method known in the art.
  • host cells provided herein are cultured under conditions that allow the host cells to express the heavy and light chains of the antibody.
  • the method further comprises the step of recovering the antibodies produced.
  • compositions can be included in compositions, more particularly in pharmaceutical compositions such as pharmaceutical preparations, so as to be used for various purposes according to actual needs. Therefore, in yet another aspect, the present invention also provides a composition, such as a pharmaceutical composition, said composition comprising the antibody or fragment thereof, nucleic acid molecule, vector and/or host cell of the present invention, and optionally Pharmaceutically acceptable excipients.
  • the anti-CD3 antibody provided by the present invention has a reduced affinity to the antigen CD3, and after the heavy chain variable region and light chain variable region contained in it are constructed together with antibodies against other antigens to form a bispecific antibody, T cells can still be effectively recruited at the tumor cell site to achieve a good therapeutic effect. Therefore, the antibodies or fragments thereof (eg, functional regions) can be used to construct multispecific, especially bispecific antibodies, which function to bind CD3 on the surface of T cells to effectively recruit T cells without overstimulating T cells.
  • the present invention also provides the anti-CD3 antibody or fragment thereof, nucleic acid molecule, vector, host cell and/or the use of the host cell in the preparation of a reagent for recruiting and activating T cells.
  • the present invention provides the use of the combination of polypeptide 1 and polypeptide 2 in the preparation of a multispecific antibody construct, or in the preparation of a reagent for recruiting and activating T cells.
  • the polypeptide 1 comprises the amino acid sequence (TYAMN) shown in SEQ ID NO:22, the amino acid sequence (RIRSKYNNYATYYADSVKD) shown in SEQ ID NO:23, the amino acid sequence (HGNFGNSYVSYFAY) shown in SEQ ID NO:24; and
  • the polypeptide 2 comprises the amino acid sequence shown in SEQ ID NO: 25 (RSSTGAVTTSNYAN), the amino acid sequence shown in SEQ ID NO: 26 (GTNKRAP), the amino acid sequence shown in SEQ ID NO: 27 (ALWYSNLWV).
  • said polypeptide 1 comprises the amino acid sequence shown in SEQ ID NO: 7 or an amino acid sequence having at least 75% identity with said amino acid sequence
  • said polypeptide 2 comprises the amino acid sequence shown in SEQ ID NO: 8 or An amino acid sequence having at least 75% identity with said amino acid sequence; preferably, in said multispecific antibody construct, said polypeptide 1 and polypeptide 2 serve as the heavy chain variable region and light chain variable region in the antibody construct, respectively chain variable regions to form the binding domain that binds CD3.
  • the CD3 is CD3 on the surface of human T cells.
  • said multispecific antibody construct is a bispecific antibody construct.
  • the multispecific antibody construct further comprises domains for binding to other antigens; further preferably, the other antigens are tumor-associated antigens, such as GPRC5D, Her2, HER3, BCMA, CLDN18, TROP2, PDL1, DLL3, CD25, EGFR, CCR8, CXCR4, CD123, Ep-CAM, CD19, CD20, GPC-3, PSMA, CD371 or VEGFR2.
  • tumor-associated antigens such as GPRC5D, Her2, HER3, BCMA, CLDN18, TROP2, PDL1, DLL3, CD25, EGFR, CCR8, CXCR4, CD123, Ep-CAM, CD19, CD20, GPC-3, PSMA, CD371 or VEGFR2.
  • the invention provides a multispecific antibody construct comprising a first binding domain that binds a first antigen and comprising a second binding domain that binds a second antigen. domain, wherein the first antigen is a tumor-associated antigen, and the second antigen is CD3.
  • the first antigen is GPRC5D, Her2, HER3, BCMA, CLDN18, TROP2, PDL1, DLL3, CD25, EGFR, CCR8, CXCR4, CD123, Ep-CAM, CD19, CD20, GPC-3, PSMA, CD371 or VEGFR2.
  • the tumor-associated antigen is a group 5 D member of the G protein-coupled receptor family class C (GPRC5D).
  • the second antigen is CD3 on the surface of human T cells.
  • the second binding domain comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region (VH) and light chain variable regions (VL) comprising the following CDR combinations (HCDR-1, HCDR-2, HCDR-3; LCDR-1, LCDR-2, LCDR-3): comprising those shown in SEQ ID NO: 22 HCDR-1 comprising the amino acid sequence (TYAMN), HCDR-2 comprising the amino acid sequence shown in SEQ ID NO:23 (RIRSKYNNYATYYADSVKD), HCDR-3 comprising the amino acid sequence (HGNFGNSYVSYFAY) shown in SEQ ID NO:24; and , LCDR-1 comprising the amino acid sequence (RSSTGAVTTSNYAN) shown in SEQ ID NO:25, LCDR-2 comprising the amino acid sequence (GTNKRAP) shown in SEQ ID NO:26, comprising the amino acid sequence shown in SEQ ID NO:27 (AL
  • said heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 7 or an amino acid sequence having at least 75% identity to said amino acid sequence; and/ Alternatively, the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 8 or an amino acid sequence at least 75% identical to said amino acid sequence.
  • the multispecific antibody is a bispecific antibody.
  • the first binding domain comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region (VH) and light chain variable region (VL) comprising a combination of CDRs selected from the following (HCDR-1, HCDR-2, HCDR-3; LCDR1, LCDR-2, LCDR-3):
  • HCDR-1 comprising the amino acid sequence (SDYAWN) shown in SEQ ID NO:28
  • HCDR-2 comprising the amino acid sequence (YISYSGSATYSPSLKS) shown in SEQ ID NO:29, comprising HCDR-2 shown in SEQ ID NO:30 HCDR-3 of the amino acid sequence (GGIAGRGRWGAMDY)
  • LCDR-1 comprising the amino acid sequence (KASQNVGTNVA) shown in SEQ ID NO:31
  • LCDR-2 comprising the amino acid sequence (SASYRDS) shown in SEQ ID NO:32
  • LCDR-3 comprising the amino acid sequence (QQYKSYPLT) shown in SEQ ID NO:33
  • SDYAWN amino acid sequence
  • YISYSGSATYSPSLKS amino acid sequence
  • LCDR-1 comprising the amino acid sequence (KASQNVGTNVA) shown in SEQ ID NO:31
  • LCDR-2 comprising the amino acid sequence (SASYRDS) shown in SEQ ID NO:32
  • LCDR-3 comprising the
  • HCDR-1 comprising the amino acid sequence (SYTIQ) shown in SEQ ID NO:34
  • HCDR-2 comprising the amino acid sequence (YIIPSSGYTNYNQKFKD) shown in SEQ ID NO:35
  • HCDR-2 comprising the amino acid sequence shown in SEQ ID NO:36
  • HCDR-3 of the amino acid sequence (NYGNWGFTY);
  • LCDR-1 comprising the amino acid sequence (KASQNVGSAVT) shown in SEQ ID NO:37
  • LCDR-2 comprising the amino acid sequence (SASNRYT) shown in SEQ ID NO:38
  • LCDR-3 comprising the amino acid sequence (QQYSNYPLT) shown in SEQ ID NO:39;
  • HCDR-1 comprising the amino acid sequence (YYVMH) shown in SEQ ID NO:40, HCDR-2 comprising the amino acid sequence (YINPYNDGTKYNEKFKG) shown in SEQ ID NO:41, HCDR-2 comprising the amino acid sequence shown in SEQ ID NO:42 HCDR-3 of the amino acid sequence (GGVRRYFDY); and, LCDR-1 comprising the amino acid sequence (RASQDIGSNLN) shown in SEQ ID NO:43, LCDR-2 comprising the amino acid sequence (ATSSLDS) shown in SEQ ID NO:44, LCDR-3 comprising the amino acid sequence (LQYATFPYT) shown in SEQ ID NO:45; and
  • HCDR-1 comprising the amino acid sequence (YYVIH) shown in SEQ ID NO:46
  • HCDR-2 comprising the amino acid sequence (YINPYNAGTKYNEKFKG) shown in SEQ ID NO:47, comprising HCDR-2 shown in SEQ ID NO:42 HCDR-3 of the amino acid sequence (GGVRRYFDY); and, comprising the amino acid sequence (RASQDIGSNLN) shown in SEQ ID NO:43
  • LCDR-2 comprising the amino acid sequence (ATSSLDS) shown in SEQ ID NO:44, comprising the amino acid sequence shown in SEQ ID NO:44 LCDR-3 of the amino acid sequence (LQYATFPYT) of ID NO:45.
  • the heavy chain variable region and the light chain variable region comprise a combination of sequences selected from:
  • amino acid sequence shown in SEQ ID NO:9 or an amino acid sequence having at least 75% identity with the amino acid sequence shown in SEQ ID NO:9; and, the amino acid sequence shown in SEQ ID NO:10 or the amino acid sequence shown in SEQ ID NO:10 An amino acid sequence having at least 75% identity to the amino acid sequence of SEQ ID NO: 10;
  • amino acid sequence shown in SEQ ID NO: 11 or an amino acid sequence having at least 75% identity with the amino acid sequence shown in SEQ ID NO: 11; and, the amino acid sequence shown in SEQ ID NO: 12 or the amino acid sequence shown in SEQ ID NO: 12 An amino acid sequence having at least 75% identity to the amino acid sequence of SEQ ID NO: 12;
  • amino acid sequence shown in SEQ ID NO: 13 or an amino acid sequence having at least 75% identity with the amino acid sequence shown in SEQ ID NO: 13; and, the amino acid sequence shown in SEQ ID NO: 14 or the amino acid sequence shown in SEQ ID NO: 14 an amino acid sequence having at least 75% identity to the amino acid sequence of SEQ ID NO: 14;
  • amino acid sequence shown in SEQ ID NO: 15 or an amino acid sequence having at least 75% identity with the amino acid sequence shown in SEQ ID NO: 15; and, the amino acid sequence shown in SEQ ID NO: 16 or the amino acid sequence shown in SEQ ID NO: 16 An amino acid sequence having at least 75% identity to the amino acid sequence of SEQ ID NO: 16.
  • bispecific antibody construct provided by the present invention comprises four polypeptide chains:
  • heavy chain 1 said heavy chain 1 comprising domains arranged according to VH-CH1-CH2-CH3 from the N-terminus to the C-terminus;
  • heavy chain 2 said heavy chain 2 comprising domains arranged according to VL-CH1-CH2-CH3 from N-terminus to C-terminus;
  • light chain 2 comprising domains arranged according to VH-CL from N-terminus to C-terminus;
  • the pairing of VH and VL contained in heavy chain 1 and light chain 1 forms the first binding domain that binds tumor-associated antigen; the pairing of VL and VH contained in heavy chain 2 and light chain 2 forms the first binding domain that binds to CD3.
  • Second binding domain The schematic diagram of the structure of the bispecific antibody construct provided by the present invention is shown in FIG. 1 .
  • the CH1-CH2-CH3 domain in the heavy chain 1 comprises the amino acid sequence shown in SEQ ID NO: 19 or the amino acid sequence An amino acid sequence having at least 75% identity;
  • the CH1-CH2-CH3 domain in heavy chain 2 comprising the amino acid sequence shown in SEQ ID NO: 20 or an amino acid sequence having at least 75% identity to said amino acid sequence;
  • the CL domain in chain 1 comprises the amino acid sequence shown in SEQ ID NO: 18 or an amino acid sequence at least 75% identical to said amino acid sequence;
  • the CL domain in light chain 2 comprises the amino acid sequence shown in SEQ ID NO: 21 or an amino acid sequence having at least 75% identity to said amino acid sequence.
  • the present invention provides a novel anti-CD3 antibody, which is obtained by humanizing the sequences of known mouse antibodies.
  • the anti-CD3 antibody provided by the invention has a reduced affinity to the antigen CD3; After bispecific antibodies are constructed with antibodies against other antigens (such as tumor-associated antigens), they can still effectively recruit T cells at tumor cell sites and achieve good therapeutic effects.
  • Figure 1 is a schematic diagram of the structure of an anti-human GPRC5D ⁇ CD3 bispecific antibody.
  • Figure 2 shows the detection results of the affinity between anti-CD3 antibody and CD3, wherein 2-1: GPRC5D ⁇ CD3 JNJ; 2-2: SP34V1 (hz); 2-3: SP34 (chi).
  • Figure 3 shows the affinity test results of anti-GPRC5D antibody and GPRC5D, wherein 3-1: GPRC5D ⁇ CD3 JNJ; 3-2: 9D7 (hz); 3-3: 26D1 (hz); 3-4: 24F5 (hz); 3-5: 6E97 (hz).
  • FIG. 4 shows the detection results of bispecific antibody-mediated T cell killing, wherein 4-1: co-culture experiment 1; 4-2: co-culture experiment 2; 4-3: co-culture experiment 3.
  • the anti-human GPRC5D ⁇ CD3 bispecific antibody was constructed by using the GPRC5D-targeting domain and the CD3-targeting domain of Johnson & Johnson's Talquetamab (JNJ-64407564).
  • the structural diagram of the bispecific antibody is shown in Figure 1, in which the structural domains contained in each chain are as follows from the N-terminal to the C-terminal: heavy chain 1: VH-CH1-CH2-CH3
  • Heavy chain 2 VL-CH1-CH2-CH3
  • the heavy chain variable region sequence (SEQ ID NO.10 in US10066015B2) and the light chain variable region sequence (SEQ ID NO.5 in US10066015B2) of the following mouse antibody were obtained from the patent US10066015B2.
  • the following human germline sequences were selected as templates for the heavy chain and light chain: IGHV3-11 and IGKV1-39. Homology modeling was performed on the A1 antibody, and the structural simulation of the Fab region was performed. After homology modeling calculations, the predicted Fab structure of the A1 antibody was finally obtained.
  • the original mouse amino acids are retained. All substitutions were made with corresponding IGKV1-39 template human amino acids.
  • the obtained humanized sequence is as follows (wherein the heavy chain and light chain CDRs are shown in bold and underlined, which are obtained according to the KABAT definition method):
  • VH/HCDR-1/HCDR-2/HCDR-3 SEQ ID NO:7/22/23/24)
  • VL/LCDR-1/LCDR-2/LCDR-3 SEQ ID NO:8/25/26/27)
  • sequence shown in SEQ ID NO: 17 was used as the heavy chain constant region
  • sequence shown in SEQ ID NO: 18 was used as the light chain constant region.
  • primers were redesigned to synthesize the corresponding humanized antibody heavy chain and The coding gene of the light chain is connected into the eukaryotic expression vector, the recombinant vector is transformed into Escherichia coli competent cells, cultivated overnight at 37°C, and single-clonal strains are sequenced and identified. The strain with the correct sequence was selected to obtain the recombinant vector, which was transfected into mammalian expression cell 293F, and cultured for 7 days at 37°C and 5% CO2.
  • SP34V1 a chimeric antibody was obtained based on the heavy and light chain variable region sequences of the above murine antibody in the patent US10066015B2, named SP34V1 (hz). It is SP34(chi).
  • the humanized antibody, chimeric antibody and bispecific antibody GPRC5D ⁇ CD3 JNJ were prepared into a solution with a concentration of 10 ⁇ g/mL in PBS buffer, and the antibody was captured using an AHC chip according to the instructions of Fortebio.
  • the human CD3 protein prepared in advance Kerijia Biology, Cat. No. GPR-HM05P
  • the specific conditions are: flow rate 30 ⁇ l/min; antigen-antibody binding time 200 seconds, dissociation time 500 seconds.
  • the measured results were fitted with the instrument-specific supporting software to analyze the affinity of the antibody to the antigen. The results are shown in Table 1 and 2-1 to 2-3 in Fig. 2 .
  • Example 3 The acquisition and detection of anti-human GPRC5D antibody
  • Human GPRC5D (Kangyuan Bochuang Biotechnology (Beijing) Co., Ltd. (kyinno company), Cat. No. KC-1583) were prepared into a cell suspension in PBS containing 2% FBS, and used as an antigen to immunize mice.
  • the mouse antibody with high affinity to the antigen human GPRC5D was obtained by screening hybridoma cells, and then the heavy and light chain variable regions of the mouse antibody were humanized to obtain humanized VH and VL sequences.
  • Example 2 the sequence shown in SEQ ID NO: 17 is also used as the heavy chain constant region, and the sequence shown in SEQ ID NO: 18 is used as the light chain constant region, and humanized VH and VL sequences are used to obtain 4 strains
  • the humanized antibodies against human GPRC5D are named 9D7 (hz), 26D1 (hz), 24F5 (hz), and 6E97 (hz) respectively, and the sequences of their respective heavy chain and light chain variable regions are as follows:
  • the antibody was prepared into a solution with a concentration of 10 ⁇ g/mL using PBS buffer, and the AHC chip was used to capture the antibody according to the instructions of Fortebio.
  • the human GPRC5D protein prepared in advance Kerijia Biology, Cat. No. GPR-HM05P
  • the specific conditions are: flow rate 30 ⁇ l/min; antigen-antibody binding time 200 seconds, dissociation time 500 seconds.
  • the measured results were fitted with the instrument-specific supporting software to analyze the affinity of the antibody to the antigen. The results are shown in Table 2 and 3-1 to 3-5 in Fig. 3 .
  • a bispecific antibody was constructed using the VH and VL of the anti-CD3 antibody and the VH and VL of the anti-GPRC5D antibody provided by the present invention.
  • the VH in heavy chain 1 and the VL in light chain 1 are replaced by humanized antibodies 9D7(hz), 26D1(hz), 24F5(hz) and 6E97, respectively (hz) VH and VL, the VL in the heavy chain 2 and the VH in the light chain 2 were replaced with the VH and VL of the humanized antibody SP34V1 (hz).
  • the obtained bispecific antibodies were named as GPRC5D ⁇ CD3 9D7(hz), GPRC5D ⁇ CD3 26D1(hz), GPRC5D ⁇ CD3 24F5(hz), and GPRC5D ⁇ CD3 26D1(hz).
  • PBMC and CD3/CD28 magnetic beads were mixed in RPMI1640 containing 10 ng/ml IL-2 and 10% FBS at a quantity ratio of 2:1, cultured and expanded for 7 days to activate T cells.
  • Co-culture experiment 1 293T LDHA-Hibit-GPRC5D cells (kyinno, product number KC-2151) were plated (96-well plate) one day in advance, and then 10,000 of the above T cells were added to each well, and different concentrations of positive control antibody GPRC5D were added ⁇ CD3 JNJ and the bispecific antibody of the present invention (1, 0.1, 0.01, 0.001, 0.0001, 0.00001, 0.000001, 0.0000001 ⁇ g/ml) were co-cultured in 18 RPMI1640 containing 10ng/ml IL-2 and 10% FBS Hour. use HiBiT Extracellular Reagent (Promega, Cat. No.
  • N2420 detects LDHA-HIBIT released from dead cells in the supernatant, thereby detecting the ratio of killer cells.
  • two groups of controls were set up for each of the two antibodies: 293T LDHA-Hibit-GPRC5D cells and antibodies were added, but T cells were not added; 293T LDHA-Hibit cells (kyinno company), T cells and antibodies were added to exclude non-antibody mediated killing and antibody-mediated non-T cell killing. The results are shown in 4-1 in Fig. 4.
  • Co-culture experiment 2 NCI-H929 (expressing GPRC5D) and K562 cells (not expressing GPRC5D) were stained with CFSE and named CFSE-H929 and CFSE-K562, respectively.
  • Co-culture experiment 3 wild-type NCI-H929 (kyinno company, product number KC-0629) and GPRC5D knockout NCI-H929 cells (kyinno company, product number KC-2203) were stained with CFSE, named CFSE-H929 and CFSE respectively -H929GPRC5DKO.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un anticorps anti-CD3. L'anticorps anti-CD3 fourni a une affinité réduite pour l'antigène CD3. En outre, après la construction de l'anticorps anti-CD3 conjointement avec un anticorps qui cible d'autres antigènes de façon à former un anticorps bispécifique, des cellules T peuvent encore être efficacement recrutées au niveau de sites de cellules tumorales, ce qui permet d'obtenir un excellent effet de traitement. Par conséquent, l'anticorps anti-CD3 fourni ou un fragment de celui-ci peut être utilisé pour construire un anticorps multispécifique, en particulier un anticorps bispécifique, et a pour effet de lier la surface de cellule CD3 de façon à recruter efficacement des cellules sans excès de cellules T.
PCT/CN2022/143043 2021-12-31 2022-12-28 Anticorps humanisé anti-cd3 et son utilisation dans la préparation d'un anticorps bispécifique Ceased WO2023125729A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111670032 2021-12-31
CN202111670032.9 2021-12-31

Publications (1)

Publication Number Publication Date
WO2023125729A1 true WO2023125729A1 (fr) 2023-07-06

Family

ID=86968100

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/143043 Ceased WO2023125729A1 (fr) 2021-12-31 2022-12-28 Anticorps humanisé anti-cd3 et son utilisation dans la préparation d'un anticorps bispécifique

Country Status (2)

Country Link
CN (1) CN116375868A (fr)
WO (1) WO2023125729A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025113643A1 (fr) 2023-12-01 2025-06-05 Gilead Sciences Inc. Protéine de fusion anti-fap-light et utilisation associée
WO2025259871A1 (fr) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anticorps anti-ccr8 et leurs utilisations

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104592392A (zh) * 2015-01-21 2015-05-06 武汉友芝友生物制药有限公司 一种双特异性抗体EpCAM×CD3的构建及应用
CN104592391A (zh) * 2015-01-21 2015-05-06 武汉友芝友生物制药有限公司 一种双特异性抗体EpCAM×CD3的构建及应用
CN104592393A (zh) * 2015-01-21 2015-05-06 武汉友芝友生物制药有限公司 一种双特异性抗体cd19×cd3的构建及应用
CN104829728A (zh) * 2015-01-21 2015-08-12 武汉友芝友生物制药有限公司 一种双特异性抗体her2xcd3的构建及应用
CN104829726A (zh) * 2015-01-21 2015-08-12 武汉友芝友生物制药有限公司 一种双特异性抗体cd19xcd3的构建及应用
CN104829725A (zh) * 2015-01-21 2015-08-12 武汉友芝友生物制药有限公司 一种双特异性抗体cd133×cd3的构建及应用
CN104829727A (zh) * 2015-01-21 2015-08-12 武汉友芝友生物制药有限公司 一种双特异性抗体cd19×cd3的构建及应用
CN105555804A (zh) * 2013-08-07 2016-05-04 阿菲姆德股份有限公司 对EGFRvIII有特异性的抗体结合位点
CN106794266A (zh) * 2014-07-01 2017-05-31 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白
CN107001468A (zh) * 2014-08-07 2017-08-01 艾芙美德有限公司 Cd3结合结构域
CN108289949A (zh) * 2015-05-29 2018-07-17 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白质的使用方法
CN108883180A (zh) * 2016-02-05 2018-11-23 奥里尼斯生物科学公司 Clec9a结合剂及其用途
CN109715667A (zh) * 2016-07-20 2019-05-03 詹森药业有限公司 抗-gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子及其用途
CN110462038A (zh) * 2017-02-07 2019-11-15 第一三共株式会社 抗gprc5d抗体和包含所述抗体的分子
CN110573172A (zh) * 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
CN110577603A (zh) * 2019-08-15 2019-12-17 北京东方百泰生物科技有限公司 一种抗cd3和抗cd19双特异性抗体
CN111788231A (zh) * 2018-02-09 2020-10-16 豪夫迈·罗氏有限公司 结合gprc5d的抗体
WO2021018859A2 (fr) * 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Anticorps se liant à gprc5d

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105555804A (zh) * 2013-08-07 2016-05-04 阿菲姆德股份有限公司 对EGFRvIII有特异性的抗体结合位点
CN106794266A (zh) * 2014-07-01 2017-05-31 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白
CN107001468A (zh) * 2014-08-07 2017-08-01 艾芙美德有限公司 Cd3结合结构域
CN104829726A (zh) * 2015-01-21 2015-08-12 武汉友芝友生物制药有限公司 一种双特异性抗体cd19xcd3的构建及应用
CN104592392A (zh) * 2015-01-21 2015-05-06 武汉友芝友生物制药有限公司 一种双特异性抗体EpCAM×CD3的构建及应用
CN104829725A (zh) * 2015-01-21 2015-08-12 武汉友芝友生物制药有限公司 一种双特异性抗体cd133×cd3的构建及应用
CN104829727A (zh) * 2015-01-21 2015-08-12 武汉友芝友生物制药有限公司 一种双特异性抗体cd19×cd3的构建及应用
CN104829728A (zh) * 2015-01-21 2015-08-12 武汉友芝友生物制药有限公司 一种双特异性抗体her2xcd3的构建及应用
CN104592393A (zh) * 2015-01-21 2015-05-06 武汉友芝友生物制药有限公司 一种双特异性抗体cd19×cd3的构建及应用
CN104592391A (zh) * 2015-01-21 2015-05-06 武汉友芝友生物制药有限公司 一种双特异性抗体EpCAM×CD3的构建及应用
CN108289949A (zh) * 2015-05-29 2018-07-17 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白质的使用方法
CN108883180A (zh) * 2016-02-05 2018-11-23 奥里尼斯生物科学公司 Clec9a结合剂及其用途
CN109715667A (zh) * 2016-07-20 2019-05-03 詹森药业有限公司 抗-gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子及其用途
CN110573172A (zh) * 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
CN110462038A (zh) * 2017-02-07 2019-11-15 第一三共株式会社 抗gprc5d抗体和包含所述抗体的分子
CN111788231A (zh) * 2018-02-09 2020-10-16 豪夫迈·罗氏有限公司 结合gprc5d的抗体
WO2021018859A2 (fr) * 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Anticorps se liant à gprc5d
CN110577603A (zh) * 2019-08-15 2019-12-17 北京东方百泰生物科技有限公司 一种抗cd3和抗cd19双特异性抗体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025113643A1 (fr) 2023-12-01 2025-06-05 Gilead Sciences Inc. Protéine de fusion anti-fap-light et utilisation associée
WO2025259871A1 (fr) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anticorps anti-ccr8 et leurs utilisations

Also Published As

Publication number Publication date
CN116375868A (zh) 2023-07-04

Similar Documents

Publication Publication Date Title
JP7790754B2 (ja) Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用
JP7765397B2 (ja) 新規抗ｌｉｌｒｂ４抗体および派生産物
TWI816729B (zh) 抗tigit抗體及其作為治療和診斷的用途
JP7737193B2 (ja) 新規抗ＣＤ３ε抗体
TWI754800B (zh) 新型抗ox40/pd-l1雙特異性抗體分子、新型抗vegf/gitr雙特異性抗體分子及其用途
US20220251214A1 (en) Bispecific Antibodies for Activation of Immune Cells
JP6994942B2 (ja) Ｔ細胞再標的化ヘテロ二量体免疫グロブリン
JP7579795B2 (ja) ＮＫｐ３０に結合する抗体分子およびその使用
TWI823895B (zh) 抗b7-h4抗體、其抗原結合片段及其醫藥用途
US11649293B2 (en) Method for enhancing humoral immune response
US11472880B2 (en) Humanized antibodies for CD3
JP2022130393A (ja) 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用
JP2017523807A (ja) 抗ｃｔｌａ４モノクローナル抗体またはその抗原結合断片、医薬組成物および使用
CN113906052A (zh) 一种抗ceacam5的单克隆抗体及其制备方法和用途
US20240392024A1 (en) Anti-tnfr2 monoclonal antibody and application thereof
JP2023539645A (ja) Ｎｋｐ３０に結合する抗体分子およびその使用
WO2023125728A1 (fr) Anticorps anti-gprc5d et son utilisation
IL304096A (en) Pd-1 binding molecule and application thereof
WO2023125729A1 (fr) Anticorps humanisé anti-cd3 et son utilisation dans la préparation d'un anticorps bispécifique
WO2023088337A1 (fr) Anticorps bispécifique contre tigit et pd-l1, composition pharmaceutique de celui-ci et son utilisation
WO2023273914A1 (fr) Anticorps anti-cd3 et son utilisation
RU2808138C1 (ru) Антитело, нацеливающееся на cd3, биспецифическое антитело и их применение
WO2025113640A1 (fr) Anticorps se liant à lilrb1/2 ou pd1-lilrb1/2 et son utilisation
JP2025540657A (ja) 抗ｃｄ３抗体
CN118725113A (zh) 一种靶向cd3的抗体或其抗原结合片段及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22914979

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22914979

Country of ref document: EP

Kind code of ref document: A1